TCRX (TScan Therapeutics) Other Stockholders Equity: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRX TScan Therapeutics Inc TCRX
44 GF Score
Price $0.73
GF Value $1.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is TScan Therapeutics Other Stockholders Equity?

TScan Therapeutics TCRX -3.15% 44 Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review.

TScan Therapeutics's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $-0.00 Mil.

TScan Therapeutics's quarterly Other Stockholders Equity increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil) but then declined from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($-0.00 Mil).

TScan Therapeutics's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

TScan Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for TScan Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TScan Therapeutics Other Stockholders Equity Chart

TScan Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TScan Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 -0.00
TCRX
44GF Score
TScan Therapeutics Inc TCRX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TScan Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
TScan Therapeutics (TCRX) has a Other Stockholders Equity of $-0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on TScan Therapeutics and its competitors.
Is TScan Therapeutics' Other Stockholders Equity too high?
TScan Therapeutics' current Other Stockholders Equity is $-0.00 Mil. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Other Stockholders Equity compare to MCRB and HYPD?
TScan Therapeutics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on TScan Therapeutics and its competitors. TScan Therapeutics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Other Stockholders Equity is $-0.00 Mil. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TScan Therapeutics (TCRX) Overvalued in 2026?

Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued. The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32. GuruFocus considers TScan Therapeutics to be Possible Value Trap.

Key valuation signals for TCRX:

  • Other Stockholders Equity: $-0.00 Mil
  • GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TScan Therapeutics Business Description

Address 830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score

Get the complete analysis for TCRX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$1.32
GF Value